METHOD OF SPERMATOZOA RECOVERY DOES NOT CORRELATE WITH EMBRYONIC MOSAICISM IN PATIENTS WITH SEVERE MALE FACTOR INFERTILITY

Tamar Alkon-Meadows, M.D.1, Carlos Hernandez-Nieto, MD1, Joseph Lee, BA1, Richard E. Slifkin, B.A.1, Natan Bar-Chama, M.D.1, Martha Luna Rojas, M.D.2, Alan B Copperman, M.D.3 and Erkan Buyuk, M.D.1, (1)Reproductive Medicine Associates of New York, New York, NY, (2)RMA of New York, International Mexico, SC, Ciudad De Mexico, Lomas De Bezares, Mexico, (3)Icahn School of Medicine at Mount Sinai/Reproductive Medicine Associates of New York, New York, NY

Title: METHOD OF SPERMATOZOA RECOVERY DOES NOT CORRELATE WITH EMBRYONIC MOSAICISM IN PATIENTS WITH SEVERE MALE FACTOR INFERTILITY

Submitter's E-mail Address: talkon@rmany.com

Preferred Presentation Type: Oral or Poster

Study Type: Retrospective Cohort Study (includes comparator groups)

Category - Subcategory(ies): Reproductive Urology: Surgery

Funding: None

* Submission of an abstract for consideration for presentation implies that the presenting author & associated co-authors have legal and ethical rights to submit and present this work. Plagiarism and submitting work that an author has no rights to, will result in an investigation and penalty.

* I verify that I am in compliance with HIPAA standards to protect the privacy of the patients discussed in my presentation(s). I either have received written authorization from the patient, have removed any identifiable images or patient records from my presentation, or my presentation does not pertain to patient treatment.

Permissions - Prior Publication or Presentation
This abstract contains original work, not published or presented previously at a meeting of another national or international scientific organization prior to this meeting and has not been submitted for publication at the time of this submission.

ACCME Disclosure
Nothing to disclose. No off-label or otherwise non-approved product use.

Did this abstract require approval by a local Institutional Review Board (IRB) or equivalent?
This abstract has been approved by a local Institutional Review Board (IRB) or equivalent.

This data will be submitted for separate scientific abstract and video presentations. The two presentations are NOT identical.
Agree

Applying for an award
Trainee: No

Abstract Category: Reproductive Urology
OBJECTIVE:

The prevalence of embryo mosaicism does not seem to be determined by the same rules that govern embryo aneuploidy, as it is neither associated with meiotic errors nor maternal age. Recent publications found higher mosaicism rates in patients with severe male factor infertility, although the underlying biological mechanism remains unknown. Some authors suggest that surgical retrieved sperm improves ploidy outcomes in patients undergoing invitro fertilization (IVF) with preimplantation genetic testing for aneuploidy (PGT-A) by reducing free oxygen radicals and DNA fragmentation. However, there are currently no publications associating rates of embryonic mosaicism to the source of sperm. Hence, the objective of this study is to examine the association between embryonic mosaicism and the method of spermatozoa recovery in infertile couples with severe male factor infertility undergoing IVF/PGT-A.

MATERIALS AND METHODS:

This retrospective, single center academic center study included all couples with severe male factor infertility undergoing IVF-PTG-A from 2019 to 2023. Cohorts were separated based on the source of sperm (testicular (TESE) vs. ejaculate). Cases with history of vasectomy, frozen/thawed semen samples, and patients harboring chromosomal rearrangements were excluded from the analysis. Primary outcome was embryo mosaicism status, secondary outcome included the level of mosaicism. Demographic characteristics, cycle characteristics and embryologic data were collected. Student’s t-test, chi-square test, Wilcoxon rank test and multivariate logistic regression were used for data analysis.

RESULTS:

A total of 1591 blastocysts derived from 432 IVF/PGT-A cycles were analyzed. 141 cases (n=471 embryos) utilized testicular sperm and 291 (n=1120 embryos) used ejaculate sperm. Male and female age were significantly higher in patients that used testicular sperm compared to ejaculate sperm (44.2 ±4, 38.5±7, p=0.0007; 36.1 ±3, 35.3±4, p=0.04 respectively). No other significant differences were found in demographic and stimulation parameters between cohorts. Patients that underwent TESE had lower fertilization and blastulation rates compared to ejaculate sperm (62.2%, 73.2%, p=0.004; 66.8%, 71.4%, p=0.02 respectively) Embryonic mosaicism rates were comparable between the two populations (TESE 0.9 % n=43/471; ejaculate 1.0% n=119/1120, p=0.69). When analyzing the grade of mosaicism both cohorts had on average more high-level than low level mosaic embryos (TESE 65.5%, ejaculate 64.7%, p= 0.32; TESE 34.5%,ejaculate 35.3%, p=0.68). After adjusting for male patient's and female patient age, fertilization and blastulation rates, there was no association with surgically extracted sperm and lower odds of embryonic mosaicism (OR 0.79, CI95% 0.5-3.1).

CONCLUSIONS:

Embryo mosaicism rates were comparable among severe male factor couples undergoing IVF/PGT with TESE versus fresh ejaculate.

IMPACT STATEMENT:

The method of spermatozoa recovery does not appear to influence the rate of embryonic mosaicism in patients with severe male factor infertility.

First Presenting Author

Presenting Author

Tamar Alkon-Meadows, M.D.
Email: talkon@rmany.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Tamar Alkon -M
Second Author

Carlos Hernandez-Nieto, MD
Email: chernandez@rmany.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Carlos Hernandez Nieto
- 2022-02-15 19:09:44

Third Author

Joseph Lee, BA
Email: jlee@rmaofny.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl
Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Joseph Adam Lee
- 2022-02-15 19:09:44

CV Upload:
Joseph Lee CV.doc

Fourth Author

Richard E. Slifkin, B.A.
Email: rslifkin@rmany.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl
New York NY 10022-1009
USA

Biographical Sketch Richard Slifkin, TS(ABB), CLT(NYS) currently serves as the Clinical Embryology Associate Laboratory Director at Reproductive Medicine Associates of New York (RMA of New York). Mr. Slifkin graduated with a Bachelor’s degree in Biology from New York University in 2006 and began his career in embryology that same year. Mr Slifkin has worked at RMA of New York in many capacities, first as an assistant in the embryology laboratory before training in embryology, then as a supervisor, and now as Associate Director. During that time, Mr. Slifkin helped transition RMA of New York from day 3 biopsies to trophectoderm biopsies and now performs thousands of trophectoderm biopsies each year. He enjoys training the next generation of embryologists and has a dedication to optimizing lab operations. Mr. Slifkin holds a Technical Supervisor certification (TS) from the American Board of Bioanalysis and a Clinical Laboratory Technologist License(CLT) from New York State. In addition to his clinical work, Mr. Slifkin has coauthored multiple peer-reviewed scientific manuscripts and dozens of abstracts in the pursuit of increasing the success of assisted reproductive technologies (ART). He has presented numerous times at the annual American Society for Reproductive Medicine (ASRM) conference and is a member of ASRM, the Society of Reproductive Biologists and
Technologists (SRBT), the American Association of Bioanalysts (AAB), and the New York Metropolitan Embryology Society (NYMES).
Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Richard Slifkin
- 2022-02-15 19:09:44

Fifth Author
Natan Bar-Chama, M.D.
Email: nbarchama@gmail.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave
Fl 10
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Natan Bar-Chama
- 2022-02-15 19:09:44
Sixth Author

Martha Luna Rojas, M.D.
Email: mluna@rmany.com -- Will not be published

RMA of New York, International Mexico, SC
Prolongacion Paseo de la Reforma #2693
Torre B - Piso 10
Ciudad De Mexico Lomas De Bezares 11910
Mexico

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Martha Luna Rojas
- 2022-02-15 19:09:44

CV Upload:
CV Martha Luna English .docx

Seventh Author

Alan B Copperman, M.D.
Email: acopperman@rmany.com -- Will not be published

Icahn School of Medicine at Mount Sinai/Reproductive Medicine Associates of New York
Department of Obstetrics, Gynecology, and Reproductive Science
New York NY
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Alan B Copperman
Eighth Author

Erkan Buyuk, M.D.
Email: ebuyuk@rmaofny.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave Fl 10
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Erkan Buyuk, M.D.
- 2022-02-15 19:09:44

FINAL STEPS

1. Check spelling and contact information.
2. Make necessary corrections:
   - Click any value in the Abstract Control Panel you want to change (e.g., Title, Category/Subcategory(ies)).
   - Edit the information and click the submit button.
   - If you add another author now, this submission will be considered incomplete and will not be eligible for consideration unless or until that author has filled out a disclosure form.

3. Click here to print this page now.

Conclude Submission